Skip to content

Determination of glycemic index of 2 test products in healthy subjects by using in-vivo method.

A randomized, cross-over, double blind study to determine the glycemic index of 2 test products in healthy subjects by using in-vivo method. - Determine the Glycemic Index of Malt based test products with high fibre in healthy subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039765
Enrollment
20
Registered
2022-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Horlicks Diabetes Plus: To achieve 25 gm carbohydrate, 52.3 gm of Horlicks Diabetes Plus with 250 mL of water will be consumed within 10 minutes at the time of each dosing Intervention2

Sponsors

Hindustan Unilever Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age: 18 to 45 years (both inclusive) at the time of consent. 2) Sex: Male and non-pregnant/non-lactating female. 3) Females of Childbearing potential must have a negative urine pregnancy test performed during screening. 4) Subjects having fasting blood glucose levels 5) Subjects having HbA1c level 6) Subjects with Body Mass Index of 18.5 to 22.9 kg/m2 (both inclusive). 7) Subject is in good general health as determined by the Investigator based on medical history and vital signs. 8) Subjects should be willing and able to follow the study protocol to participate in the study. 9) Subject must be able to understand and provide written informed consent to participate in the study. 10) Subject is willing to refrain from vigorous physical exercise during the study period.

Exclusion criteria

Exclusion criteria: 1) Subject with any known food allergy or intolerance to any food or beverages. 2) Subject taking any medication in the past one week. 3) Subject with presence of any chronic disease or illness in the past three months or any clinically significant on-going chronic medical illness e.g., Congestive cardiac failure, Hepatitis, Hypotensive episodes, etc. 4) Subject with recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study. 5) Subject who has participated in any clinical trial within the past 90 days with blood loss more than 450 mL. 6) Subject on an unusual diet, special diet, for whatever reason e.g., high protein diet, low sodium diet, for two weeks prior to receiving any test food and throughout subjectââ?¬•s participation in the study. 7) Subject who has performed vigorous physical exercise in the morning on dosing day. 8) Female subjects who are pregnant or who are on lactation. 9) Subjects who have tested positive for HIV test. 10) Subjects who have current or recent history (within one year of screening) of alcohol (14 units a week on a regular basis) or other substance abuse. 11) Subjects who are users of Nicotine. 12) Subjects who are currently smoking (or use nicotine containing products) or who have quit smoking (or using nicotine containing products) during the past 3 months. 13) Subjects having history of Hepatitis B or C virus.

Design outcomes

Primary

MeasureTime frame
Glycemic index of two malt-based test products with high fiber in healthy subjects, based on incremental AUC, expressed as a percentage of the average IAUC response to the same amount of carbohydrate from a reference productTimepoint: Predose baseline (i.e., at 15 mins before product consumption) & at 0 mins, 15 mins, 30 mins, 45 mins, 60 mins, 90 mins and 120 mins post product consumption

Secondary

MeasureTime frame
Satiety level (for hunger & fullness) from test products using 5-point equilateral category Likert rating scaleTimepoint: Predose baseline (i.e., at -5 mins before product consumption) & at 35 mins, 65 mins, 95 mins, 125min, 150min and 180 mins post product consumption

Countries

India

Contacts

Public ContactDr Simran Sethi

Cliantha Research

pjoshi@ofacto.com8000085049

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026